Cue Biopharma Receivables

Cue Biopharma (CUE) currently reports a receivables of $0 as of June 2026. That compares with $530K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Cue Biopharma's receivables history and peer comparisons.

Cue Biopharma's receivables decreased from $530K to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cue Biopharma reported $0 in receivables as of June 2026. That compares with $530K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cue Biopharma, and consider following CUE for alerts when major investors trade the stock.

Cue Biopharma is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CUE with unrelated industries.